These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23902231)

  • 21. Endocannabinoids control platelet activation and limit aggregate formation under flow.
    De Angelis V; Koekman AC; Weeterings C; Roest M; de Groot PG; Herczenik E; Maas C
    PLoS One; 2014; 9(9):e108282. PubMed ID: 25264625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glabridin, a Bioactive Flavonoid from Licorice, Effectively Inhibits Platelet Activation in Humans and Mice.
    Chung CL; Chen JH; Huang WC; Sheu JR; Hsia CW; Jayakumar T; Hsia CH; Chiou KR; Hou SM
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulforaphane prevents human platelet aggregation through inhibiting the phosphatidylinositol 3-kinase/Akt pathway.
    Chuang WY; Kung PH; Kuo CY; Wu CC
    Thromb Haemost; 2013 Jun; 109(6):1120-30. PubMed ID: 23426129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ligustrazine inhibits platelet activation via suppression of the Akt pathway.
    Li L; Chen H; Shen A; Li Q; Chen Y; Chu J; Liu L; Peng J; Chen K
    Int J Mol Med; 2019 Jan; 43(1):575-582. PubMed ID: 30387814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors.
    Paul BZ; Jin J; Kunapuli SP
    J Biol Chem; 1999 Oct; 274(41):29108-14. PubMed ID: 10506165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blocking platelet aggregation inhibits thromboxane A2 formation by low dose agonists but does not inhibit phosphorylation and activation of cytosolic phospholipase A2.
    Carroll RC; Wang XF; Lanza F; Steiner B; Kouns WC
    Thromb Res; 1997 Oct; 88(2):109-25. PubMed ID: 9361365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
    Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
    Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glybenclamide: an antidiabetic with in vivo antithrombotic activity.
    Ting HJ; Khasawneh FT
    Eur J Pharmacol; 2010 Dec; 649(1-3):249-54. PubMed ID: 20858477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
    Phillips RM
    Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
    Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
    Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound.
    Ding YA; Chou TC; Chern JW; Yen MH
    Thromb Res; 1995 Feb; 77(3):291-303. PubMed ID: 7740521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
    Wu Q; Quan H; Xu Y; Li Y; Hu Y; Lou L
    J Pharmacol Exp Ther; 2012 Jun; 341(3):709-17. PubMed ID: 22414857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
    Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway.
    Dangelmaier C; Jin J; Smith JB; Kunapuli SP
    Thromb Haemost; 2001 Feb; 85(2):341-8. PubMed ID: 11246558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line.
    Ching LM; Young HA; Eberly K; Yu CR
    Biochem Pharmacol; 1999 Oct; 58(7):1173-81. PubMed ID: 10484075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P2X1-initiated p38 signalling enhances thromboxane A2-induced platelet secretion and aggregation.
    Huang Z; Liu P; Zhu L; Li N; Hu H
    Thromb Haemost; 2014 Jul; 112(1):142-50. PubMed ID: 24633352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism for antiplatelet effect of onion: AA release inhibition, thromboxane A(2)synthase inhibition and TXA(2)/PGH(2)receptor blockade.
    Moon CH; Jung YS; Kim MH; Lee SH; Baik EJ; Park SW
    Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):277-83. PubMed ID: 10883058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.